Novo Nordisk has transferred its discontinued Parkinson’s therapy to AI biotech startup Cellular Intelligence, retaining equity and milestone rights instead of making a traditional sale. The...
The approval of the treatment is based on two pivotal phase III clinical trials: M15-741 and M-15-736. Primary endpoint results from the first trial showed that...